Literature DB >> 16254059

Medication-free research in early episode schizophrenia: evidence of long-term harm?

John R Bola1.   

Abstract

This study investigates the question of whether short periods of medication-free research in early episode schizophrenia result in demonstrable long-term harm to human subjects. A meta-analysis of published quasi-experimental and random assignment studies that had a majority of first- or second-episode schizophrenia spectrum subjects, at least 1 initially unmedicated group, and a minimum of 1-year results was conducted. Only 6 studies, with 623 subjects, met inclusion criteria. The initially unmedicated groups showed a small, statistically nonsignificant long-term advantage (r = -0.09). Incorporating only random assignment studies into a composite effect size produced a similar near-zero result (r = 0.01). Good-quality evidence is inadequate to support a conclusion of long-term harm resulting from short-term postponement of medication in early episode schizophrenia research. A categorical prohibition against such research should be reconsidered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254059      PMCID: PMC2632227          DOI: 10.1093/schbul/sbj019

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  70 in total

1.  The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia.

Authors:  William T Carpenter; Paul S Appelbaum; Robert J Levine
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

Review 2.  Maintenance medication for schizophrenia: strategies for dose reduction.

Authors:  N R Schooler
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

3.  Does short term placebo treatment of chronic schizophrenia produce long term harm?

Authors:  D A Curson; S R Hirsch; S D Platt; R W Bamber; T R Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-20

Review 4.  Neuroleptics and the natural course of schizophrenia.

Authors:  R J Wyatt
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

5.  Publication bias: the problem that won't go away.

Authors:  K Dickersin; Y I Min
Journal:  Ann N Y Acad Sci       Date:  1993-12-31       Impact factor: 5.691

6.  Neuroleptic withdrawal in schizophrenic patients. A review of the literature.

Authors:  P L Gilbert; M J Harris; L A McAdams; D V Jeste
Journal:  Arch Gen Psychiatry       Date:  1995-03

Review 7.  Research on first-episode psychosis: report on a National Institute of Mental Health Workshop.

Authors:  D G Kirch; S J Keith; S M Matthews
Journal:  Schizophr Bull       Date:  1992       Impact factor: 9.306

8.  Are there schizophrenics for whom drugs may be unnecessary or contraindicated?

Authors:  M Rappaport; H K Hopkins; K Hall; T Belleza; J Silverman
Journal:  Int Pharmacopsychiatry       Date:  1978

9.  Duration of untreated psychosis and cognitive deterioration in first-episode schizophrenia.

Authors:  G P Amminger; J Edwards; W J Brewer; S Harrigan; P D McGorry
Journal:  Schizophr Res       Date:  2002-04-01       Impact factor: 4.939

10.  Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia.

Authors:  Beng-Choon Ho; Daniel Alicata; Julianna Ward; David J Moser; Daniel S O'Leary; Stephan Arndt; Nancy C Andreasen
Journal:  Am J Psychiatry       Date:  2003-01       Impact factor: 18.112

View more
  8 in total

1.  Ethics of medication-free research in schizophrenia.

Authors:  Donna T Chen; Jonathan D Moreno
Journal:  Schizophr Bull       Date:  2006-02-08       Impact factor: 9.306

2.  Implications for future research of "medication-free research in early episode schizophrenia".

Authors:  Nina R Schooler
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

Review 3.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 4.  New Paradigms of Old Psychedelics in Schizophrenia.

Authors:  Danish Mahmood; Sattam K Alenezi; Md Jamir Anwar; Faizul Azam; Kamal A Qureshi; Mariusz Jaremko
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-23

Review 5.  A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia.

Authors:  Tim Calton; Michael Ferriter; Nick Huband; Helen Spandler
Journal:  Schizophr Bull       Date:  2007-06-14       Impact factor: 9.306

6.  How frequent is chronic multiyear delusional activity and recovery in schizophrenia: a 20-year multi-follow-up.

Authors:  Martin Harrow; Thomas H Jobe
Journal:  Schizophr Bull       Date:  2008-07-09       Impact factor: 9.306

7.  Treating older adults with schizophrenia: challenges and opportunities.

Authors:  Dilip V Jeste; Jeanne E Maglione
Journal:  Schizophr Bull       Date:  2013-04-03       Impact factor: 9.306

Review 8.  The evolution of drug development in schizophrenia: past issues and future opportunities.

Authors:  William T Carpenter; James I Koenig
Journal:  Neuropsychopharmacology       Date:  2007-11-28       Impact factor: 7.853

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.